134 related articles for article (PubMed ID: 26905833)
21. Registered report: Melanoma genome sequencing reveals frequent PREX2 mutations.
Chroscinski D; Sampey D; Hewitt A;
Elife; 2014 Dec; 3():. PubMed ID: 25490935
[TBL] [Abstract][Full Text] [Related]
22. Registered report: Interactions between cancer stem cells and their niche govern metastatic colonization.
Incardona F; Doroudchi MM; Ismail N; Carreno A; Griner E; Anna Lim M;
Elife; 2015 Jun; 4():e06938. PubMed ID: 26086719
[TBL] [Abstract][Full Text] [Related]
23. Registered report: Intestinal inflammation targets cancer-inducing activity of the microbiota.
Eaton K; Yang W;
Elife; 2015 Mar; 4():. PubMed ID: 25781343
[TBL] [Abstract][Full Text] [Related]
24. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Sharma SV; Lee DY; Li B; Quinlan MP; Takahashi F; Maheswaran S; McDermott U; Azizian N; Zou L; Fischbach MA; Wong KK; Brandstetter K; Wittner B; Ramaswamy S; Classon M; Settleman J
Cell; 2010 Apr; 141(1):69-80. PubMed ID: 20371346
[TBL] [Abstract][Full Text] [Related]
25. Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.
Chronscinski D; Cherukeri S; Tan F; Perfito N; Lomax J; Iorns E
PeerJ; 2015; 3():e1231. PubMed ID: 26401447
[TBL] [Abstract][Full Text] [Related]
26. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
27. Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Shan X; Fung JJ; Kosaka A; Danet-Desnoyers G;
Elife; 2017 Jun; 6():. PubMed ID: 28653617
[TBL] [Abstract][Full Text] [Related]
28. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
29. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
[TBL] [Abstract][Full Text] [Related]
30. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
32. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
[TBL] [Abstract][Full Text] [Related]
33. An open investigation of the reproducibility of cancer biology research.
Errington TM; Iorns E; Gunn W; Tan FE; Lomax J; Nosek BA
Elife; 2014 Dec; 3():. PubMed ID: 25490932
[TBL] [Abstract][Full Text] [Related]
34. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.
Park MY; Kim DR; Eo EY; Lim HJ; Park JS; Cho YJ; Yoon HI; Lee JH; Lee CT
J Gene Med; 2013; 15(3-4):115-22. PubMed ID: 23413016
[TBL] [Abstract][Full Text] [Related]
35. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
36. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
37. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
38. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Götze S; Coersmeyer M; Müller O; Sievers S
Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
[TBL] [Abstract][Full Text] [Related]
40. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
